NHC
XPH icon

Nicholas Hoffman & Company’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Nicholas Hoffman & Company’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,289
Closed -$448K – 173
2017
Q4 		$448K Buy
+10,289
New +$438K 0.18% 110

Other funds holding XPH

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return
AL
Arnhold LLC New York $1.43B AUM 59.3% 1-Year Est. Return

Nicholas Hoffman & Company's XPH Position: Q1 2018 in Review

Nicholas Hoffman & Company sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2018, closing a stake of 10,289 shares — an estimated $448K sold.

Nicholas Hoffman & Company first reported a position in XPH in Q4 2017 and held it in 1 quarter. The position peaked at $448K in Q4 2017. 75 funds tracked by Wall St. Rank hold XPH as of Q1 2018.

  • Nicholas Hoffman & Company reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2018 after selling out during the quarter.
  • Nicholas Hoffman & Company sold 10,289 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2018, an estimated $448K.
  • Nicholas Hoffman & Company first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2017 and held it in 1 quarter.
  • Nicholas Hoffman & Company's State Street SPDR S&P Pharmaceuticals ETF position peaked at $448K in Q4 2017.
  • 75 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2018.

Based on Nicholas Hoffman & Company's 13F filing for Q1 2018, filed 7 May 2018.